T1	Participants 151 242	320 multiple myeloma (MM) patients entering the German Myeloma Treatment Group (GMTG) trial
T2	Participants 152 332	20 multiple myeloma (MM) patients entering the German Myeloma Treatment Group (GMTG) trial MM01 were analysed for factors predicting overall (OAS) and tumour related survival (TRS)
T3	Participants 959 1114	poor prognosis patients (50% TRS: 16 months) characterised by pretreatment platelets of < or = 150,000 and/or poorly differentiated myeloma cell morphology
T4	Participants 1116 1232	Patients lacking both risk factors displayed 50% survival times of 46 months in stage III and 88 months in stage II.
